These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34398668)

  • 1. Exebacase in Addition to Daptomycin against MRSA.
    Kebriaei R; Stamper KC; Lev KL; Morrisette T; Abdul-Mutakabbir JC; Schuch R; Lehoux D; Rybak MJ
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0012821. PubMed ID: 34398668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exebacase Is Active
    Swift SM; Sauve K; Cassino C; Schuch R
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0272320. PubMed ID: 34228536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.
    Shah SU; Xiong YQ; Abdelhady W; Iwaz J; Pak Y; Schuch R; Cassino C; Lehoux D; Bayer AS
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.
    Karau MJ; Schmidt-Malan SM; Yan Q; Greenwood-Quaintance KE; Mandrekar J; Lehoux D; Schuch R; Cassino C; Patel R
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model.
    Asempa TE; Abdelraouf K; Carabeo T; Schuch R; Nicolau DP
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an
    Kunz Coyne AJ; Bleick C; Stamper K; Kebriaei R; Bayer AS; Lehman SM; Rybak MJ
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0138823. PubMed ID: 38376187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires.
    Karau MJ; Mandrekar J; Lehoux D; Schuch R; Cassino C; Patel R
    BMC Res Notes; 2023 Sep; 16(1):209. PubMed ID: 37697424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model.
    Asempa TE; DeRosa NA; Cassino C; Lehoux D; Schuch R; Nicolau DP
    J Antimicrob Chemother; 2021 Sep; 76(10):2622-2628. PubMed ID: 34223628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Steed ME; Werth BJ; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017.
    Traczewski M; Oh J; Cassino C; Schuch R
    Diagn Microbiol Infect Dis; 2019 Dec; 95(4):114879. PubMed ID: 31466875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
    Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G
    Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics.
    Oh J; Warner M; Ambler JE; Schuch R
    Microbiol Spectr; 2023 Mar; 11(2):e0526122. PubMed ID: 36862002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.